CRC has an immunosuppressive TME which prevents the development of an efficient response to ICB therapies. There exists Consequently an urgent have to identify the means reprogram this suppressive TME in an effort to improve immunotherapy efficacy. In The existing research, we used CRISPR KO screens to find out genes that sensitize CRC to antitumor